Photo: Courtesy of Shenzhen Kangtai Biological Products

The COVID-19 vaccine produced by Shenzhen Kangtai Biological Products can protect against various mutations of the novel coronavirus, including the increasingly dominant Delta variant, the company told the Global Times on Wednesday.

The company said it had recently succeeded in isolating the Delta strain and would continue to evaluate it for further vaccine development.

Kangtai's COVID-19 vaccine was approved in China for emergency use in May. The company previously announced that data collected during the Phase I and II clinical trials showed a strong antibody response.

Kangtai's vaccine is currently undergoing Phase III clinical trials in countries including Malaysia, Colombia and Pakistan.

Millions of doses of Kangtai's vaccine have been administered since June 1 in areas including South China's Guangdong and Nantong in East China's Jiangsu, according to media reports.